3,3'-dichloro-4,4'-dimethyl-biphenyl | 65758-11-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,3'-dichloro-4,4'-dimethyl-biphenyl
• 英文别名: 3,3'-Dichlor-4,4'-dimethyl-biphenyl；2-Chloro-4-(3-chloro-4-methylphenyl)-1-methylbenzene
• CAS: 65758-11-4
• 化学式: C₁₄H₁₂Cl₂
• 分子量: 251.155
• InChiKey: UEUCSNHCINRLEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  2-氯-4-碘甲苯 在 铜 作用下， 生成 3,3'-dichloro-4,4'-dimethyl-biphenyl
  参考文献：
  名称：

  315.氯苯与甲基的反应

  摘要：

  DOI：

  10.1039/jr9570001665

文献信息

• [EN] GLUCAGON ANTAGONISTS<br/>[FR] ANTAGONISTES DE GLUCAGON
  申请人：METABASIS THERAPEUTICS INC

  公开号：WO2010019830A1

  公开（公告）日：2010-02-18

  Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co- crystals and prodrugs thereof. Formula I

  本文提供了化合物，包括其对映体纯形式，以及具有胰高血糖素受体拮抗剂或逆向激动剂活性的药用盐或共晶体和前药。此外，本文提供了包括这些化合物的药物组合物，以及治疗、预防、延缓发病时间或减少一种或多种胰高血糖素受体拮抗剂适用的疾病或病情的发展或进展风险的方法，包括I型和II型糖尿病、胰岛素抵抗和高血糖。此外，本文提供了制备或生产本文披露的化合物的方法，包括其对映体纯形式，以及药用盐或共晶体和前药。公式I
• Glucagon antagonists
  申请人：Metabasis Therapeutics, Inc.

  公开号：EP2799428A2

  公开（公告）日：2014-11-05

  Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof.

  本文提供了具有胰高血糖素受体拮抗剂或反向激动剂活性的化合物（包括其对映体纯形式）及其药学上可接受的盐或共晶体和原药。此外，本文还提供了包含上述成分的药物组合物，以及治疗、预防、延缓发病时间或降低疾病或病情发展风险的方法，这些疾病或病情适用于一种或多种胰高血糖素受体拮抗剂，包括I型和II型糖尿病、胰岛素抵抗和高血糖症。此外，本文还提供了制造或生产本文公开的化合物的方法，包括其对映体纯形式，以及其药学上可接受的盐或共晶体和原药。
• Photocurable ink composition and method for forming image
  申请人：FUJIFILM CORPORATION

  公开号：US10711145B2

  公开（公告）日：2020-07-14

  A photocurable ink composition is provided, the composition including: a resin that includes at least one of a structural unit (1) below or a structural unit (2) below; and at least one of a monofunctional radical-polymerizable monomer or a bifunctional radical-polymerizable monomer, in which a total content of the monofunctional radical-polymerizable monomer and the bifunctional radical-polymerizable monomer is 50% by mass or more relative to a total amount of the photocurable ink composition.

  提供了一种光固化油墨组合物，该组合物包括：树脂，其中包括以下结构单元 (1) 或以下结构单元 (2) 中的至少一种；以及单官能团可自由基聚合单体或双官能团可自由基聚合单体中的至少一种，其中单官能团可自由基聚合单体和双官能团可自由基聚合单体的总含量相对于光固化油墨组合物的总用量为 50%（质量）或以上。
• GLUCAGON ANTAGONISTS
  申请人：Metabasis Therapeutics, Inc.

  公开号：EP2326618B1

  公开（公告）日：2014-10-15
• LYOTROPIC LIQUID CRYSTALLINE MIXTURE, COATING LIQUID, AND OPTICAL ANISOTROPIC FILM
  申请人：Matsuda Shoichi

  公开号：US20100038589A1

  公开（公告）日：2010-02-18

  The lyotropic liquid crystalline mixture of the present invention comprises at least a first azo compound and a second azo compound in relation of constitutional isomers wherein the first azo compound and the second azo compound are the constitutional isomers different in a binding site of at least an azo group. The first azo compound is preferably an azo compound wherein the azo group is bonded to an ortho-position of a hydroxyl group of an aminonaphthol skeleton. The second azo compound is preferably an azo compound wherein the azo group is bonded to an ortho-position of an amino group of an aminonaphthol skeleton. The lyotropic liquid crystalline mixture of the present invention may be utilized as a forming material of an optical anisotropic film, for example.